Clearside Biomedical (CLSD) AI Stock Analysis

• Market Cap: $38.64M
• Dividend Yield: N/A
• Average Volume (3M): 8.53M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.06
• Revenue Growth: -55.47%
• EPS Growth: 24.92%
• Country: US
• Employees: 32
• Sector: Healthcare
• Sector Strength: 41
• Industry: Biotechnology
• EPS (TTM): -0.11
• Shares Outstanding: 77,708,534
• 10 Day Avg. Volume: 25,238,239
• 30 Day Avg. Volume: 8,529,337
• PEG Ratio: -0.16
• Price to Book (P/B): -1.37
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -2.70
• Enterprise Value/Market Cap: 1.33
• Enterprise Value/Revenue: 2.48
• Enterprise Value/Gross Profit: 15.23
• Enterprise Value/Ebitda: -0.57
• 1Y Price Target: $3.67
• Price Target Upside: 634.00% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 6

• Rating: 43 Neutral
• Price Target: $0.50 ▲(0.00%Upside)

Clearside Biomedical's overall stock score is heavily impacted by its poor financial performance and challenging valuation. The bearish technical indicators and uncertain corporate restructuring efforts further contribute to a low score. The company's strategic initiatives may offer potential upside, but the risks remain significant.

Positive Factors

Clinical Trial Results

The Phase 2b ODYSSEY trial of CLS-AX in wet AMD reported positive topline results, maintaining stable BCVA and CST from baseline to Week 36.

Partnerships and Collaborations

CLSD has several partnership programs in place, ensuring continuity of support for the SCS microinjector platform.

Product Pipeline

CLSD has a commercially validated SCS platform and a competitive durable TKI asset for wet AMD that merits Ph3 investigation.

Negative Factors

Funding Challenges

Management cited challenging fundraising conditions, and the company has not been able to secure capital to fund the Phase 3 program of CLS-AX in wet AMD.

Operational Changes

All internal research and development programs will pause during this process, and employees will transition into consulting roles.

Strategic Uncertainty

CLSD's decision to explore strategic alternatives is disappointing given the company's phase 3 ready-asset (CLS-AX) for wAMD demonstrated the potential for flexible dosing.

Clearside Biomedical Business Overview & Revenue Model

Company Description

Clearside Biomedical, Inc. is a biopharmaceutical company focused on developing and commercializing therapies to treat serious eye diseases. The company specializes in utilizing its proprietary SCS Microinjector™, which allows for the precise delivery of therapeutic agents to the suprachoroidal space of the eye. This technology is designed to improve the effectiveness and safety of treatments for retinal diseases. Clearside's core pipeline includes product candidates targeting conditions such as uveitis, diabetic macular edema, and retinal vein occlusion.

How the Company Makes Money

Clearside Biomedical makes money primarily through the development and potential commercialization of its proprietary therapies for eye diseases. The company generates revenue through collaborative agreements, licensing arrangements, and milestone payments from partnerships with pharmaceutical companies. These partnerships often involve Clearside providing its SCS Microinjector™ technology to facilitate drug delivery. Additionally, the company may earn revenue from the eventual sale of approved therapies derived from its product pipeline, as well as from potential royalties on sales of partnered products.

Clearside Biomedical Financial Statement Overview

Summary

Clearside Biomedical faces significant financial challenges, with zero revenue and persistent losses. Negative equity and reliance on external finance indicate severe financial instability.

Income Statement

The company has experienced declining revenue over the years, with total revenue dropping to zero by 2024. This is coupled with persistent negative net income, indicating operational challenges. The absence of revenue growth and consistent losses suggest significant difficulties in generating profit.

Balance Sheet

The company's balance sheet shows a negative stockholders' equity, indicating financial instability. High liabilities relative to assets and negative equity highlight potential solvency concerns. The debt-to-equity ratio is not calculable due to negative equity, but the high total liabilities reflect leverage risks.

Cash Flow

The cash flow statement indicates negative free cash flow and operating cash flow over the years, reflecting challenges in cash generation from operations. Though financing activities provided some relief, reliance on external funding is unsustainable long-term.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.66M	8.23M	1.33M	29.57M	7.89M
Gross Profit	1.51M	7.87M	1.12M	29.40M	7.89M
EBITDA	-24.35M	-23.06M	-29.46M	-449.00K	-17.93M
Net Income	-34.35M	-32.48M	-34.07M	376.00K	-18.03M
Balance Sheet
Total Assets	25.13M	34.02M	51.30M	42.90M	19.32M
Cash, Cash Equivalents and Short-Term Investments	20.02M	28.92M	48.26M	30.44M	17.29M
Total Debt	703.00K	43.00M	1.28M	675.00K	1.98M
Total Liabilities	63.98M	49.93M	40.70M	4.93M	10.56M
Stockholders Equity	-38.85M	-15.91M	10.61M	37.98M	8.76M
Cash Flow
Free Cash Flow	-25.68M	-19.91M	-13.61M	-10.73M	-13.18M
Operating Cash Flow	-24.70M	-18.14M	-13.37M	-10.73M	-13.12M
Investing Cash Flow	-638.00K	-1.78M	-246.00K	0.00	-55.00K
Financing Cash Flow	16.44M	414.00K	31.33M	23.78M	7.87M

Clearside Biomedical Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.50
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CLSD, the sentiment is Negative. The current price of 0.5 is below the 20-day moving average (MA) of 0.70, below the 50-day MA of 0.77, and below the 200-day MA of 0.93, indicating a bearish trend. The MACD of -0.09 indicates Positive momentum. The RSI at 36.93 is Neutral, neither overbought nor oversold. The STOCH value of 42.13 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CLSD.

Clearside Biomedical Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	66 Neutral	CHF27.37B	16.73	9.37%	1.98%	28.68%	7.54%
ADAG	44 Neutral	$93.75M	―	-55.14%	―	-99.43%	-69.40%
IVVD	44 Neutral	$94.17M	―	-122.69%	―	―	20.91%
ADVM	44 Neutral	$56.40M	―	-127.99%	―	―	37.54%
CLSD	43 Neutral	$38.64M	―	91.63%	―	-55.47%	24.92%
JSPR	35 Underperform	$47.32M	―	-101.34%	―	―	21.40%

Clearside Biomedical Corporate Events

Clearside Biomedical Explores Strategic Alternatives Amid Economic Challenges

On July 17, 2025, Clearside Biomedical announced it is exploring strategic alternatives to enhance shareholder value, including the sale or license of assets, partnerships, or mergers. To conserve resources, all employees, including top executives, will transition to consulting roles, and internal R&D programs will be paused. The company has retained Piper Sandler to assist in this strategic evaluation process. This move comes amid challenging economic conditions and aims to advance Clearside’s proprietary suprachoroidal delivery platform and ophthalmology pipeline. The workforce reduction is expected to incur charges of approximately $3.4 million in the third quarter of 2025.

The most recent analyst rating on (CLSD) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Clearside Biomedical stock, see the CLSD Stock Forecast page.

Clearside Biomedical Approves Share Increase at Annual Meeting

On May 30, 2025, Clearside Biomedical, Inc. held its annual meeting of stockholders where several key proposals were approved. The most significant outcome was the amendment to the company’s certificate of incorporation to increase the authorized shares of common stock from 200 million to 400 million, reflecting a strategic move to potentially expand its capital base. Additionally, the election of three directors, approval of executive compensation, and the ratification of Ernst & Young LLP as the independent accounting firm for the fiscal year ending December 31, 2025, were also confirmed.

The most recent analyst rating on (CLSD) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Clearside Biomedical stock, see the CLSD Stock Forecast page.